


## Amendments to the Claims:

### **Listing of the Claims:**

1. (Currently Amended) A method for the treatment of cell proliferative disorders associated with an altered cell dependent kinase activity, comprising:

administering to a mammal in need thereof an effective amount of a compound represented by formula (I):



wherein

R is a C<sub>3</sub>-C<sub>6</sub> cycloalkyl group, which is optionally substituted with a straight or branched C<sub>1</sub>-C<sub>6</sub> alkyl group, or is a C<sub>1</sub>-C<sub>6</sub> alkyl, aryl or arylalkyl group, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulphonyl, arylamino, arylcarbonyl, N-alkyl-piperazinyl, 4-morpholinyl, perfluorinated C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl, C<sub>2</sub>-C<sub>4</sub> aminoalkynyl or C<sub>2</sub>-C<sub>4</sub> hydroxyalkynyl substituents;

R<sub>1</sub> is -(CH<sub>2</sub>)<sub>n</sub>-R<sub>3</sub>;

n is 0 or an integer from 1 to 4;

R<sub>3</sub> is hydrogen, hydroxy, amino, or it is selected from the group consisting of cycloalkyl, aryl and heterocyclyl, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulphonyl, arylamino,

arylcarbonyl, N-alkyl-piperazinyl, 4-morpholinyl, perfluorinated C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl, C<sub>2</sub>-C<sub>4</sub> aminoalkynyl or C<sub>2</sub>-C<sub>4</sub> hydroxyalkynyl substituents;

R<sub>2</sub> is hydrogen, or

R<sub>2</sub> and R<sub>1</sub>, together with the nitrogen atom to which they are bonded, form a heterocyclyl or heteroaryl group, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulphonyl, arylamino, arylcarbonyl, N-alkyl-piperazinyl, 4-morpholinyl, perfluorinated C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl, C<sub>2</sub>-C<sub>4</sub> aminoalkynyl or C<sub>2</sub>-C<sub>4</sub> hydroxyalkynyl substituents;

or a pharmaceutically acceptable salt thereof;

provided that when n is 0 and R<sub>2</sub> is hydrogen, R is a C<sub>3</sub>-C<sub>6</sub> cycloalkyl group optionally substituted with a straight or branched C<sub>1</sub>-C<sub>6</sub> alkyl group.

2. (Original) The method of Claim 1, wherein the cell proliferative disorder is selected from the group consisting of cancer, Alzheimer's disease, viral infections, autoimmune diseases and neurodegenerative disorders.

3. (Original) The method of Claim 2, wherein the cancer is selected from the group consisting of carcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system, melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratocanthoma, thyroid follicular cancer, and Kaposi's sarcoma.

4. (Original) The method of Claim 1, wherein the cell proliferative disorder is selected from the group consisting of benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis, and post-surgical stenosis and restenosis.

5. (Original) The method of Claim 1, which provides tumor angiogenesis and metastasis inhibition.

6. (Original) The method of Claim 1, which provides cell cycle inhibition or cdk/cyclin dependent inhibition.

7. (Original) The method of Claim 1, further comprising subjecting the mammal in need thereof with a radiation therapy or chemotherapy regimen in combination with at least one cytostatic or cytotoxic agent.

8. (Original) The method of Claim 1, wherein R is C<sub>3</sub>-C<sub>6</sub> cycloalkyl optionally substituted with a straight or branched C<sub>1</sub>-C<sub>6</sub> alkyl group.

9. (Original) The method of Claim 1, wherein

R is a C<sub>3</sub>-C<sub>6</sub> cycloalkyl or an optionally substituted straight or branched C<sub>1</sub>-C<sub>4</sub> alkyl group, a cycloalkyl group, an aryl group or an arylalkyl group;

R<sub>1</sub> is a C<sub>1</sub>-C<sub>4</sub> alkyl group or a phenyl, phenylalkyl, heteroaryl, heteroarylalkyl or heterocyclyl group, which is optionally substituted as defined in Claim 1;  
or a pharmaceutically acceptable salt thereof.

10. (Original) The method of Claim 1, wherein

R is a C<sub>3</sub>-C<sub>6</sub> cycloalkyl;

R<sub>1</sub> is a C<sub>1</sub>-C<sub>4</sub> alkyl group substituted by hydroxy or amino, or is an aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the aryl or heterocyclyl moiety is selected from the group consisting of phenyl or optionally benzocondensed pyridine, indole, thiophene, thiazole, isoxazole, furane, piperidine, morpholine, each optionally further substituted;  
or a pharmaceutically acceptable salt thereof.

11. (Original) The method of Claim 1, wherein R<sub>1</sub> and R<sub>2</sub>, together with the nitrogen atom to which they are bonded, form an optionally substituted heterocyclyl ring.

12. (Original) The method of Claim 11, wherein the heterocyclyl ring is piperidino, piperazino or morpholino.

13. (Original) The method of Claim 7, wherein the compound is selected from the group consisting of

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-[2-(1-piperidinyl)ethyl]urea;  
4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]carbonyl amino)methyl]benzenesulfonamide;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-[2-(2-pyridinyl)ethyl]urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-[2-(1-pyrrolidinyl)ethyl]urea;  
N-(3-chlorophenethyl)-N'-(3-cyclopropyl-1H-pyrazol-5-yl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2,3-dimethoxybenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-chlorobenzyl)urea;  
N-[3-(tert-butyl)-1H-pyrazol-5-yl]-N'-(4-piperidinylmethyl)urea;  
N-[3-(tert-butyl)-1H-pyrazol-5-yl]-N'-(3-fluorobenzyl)urea;  
N-[3-(tert-butyl)-1H-pyrazol-5-yl]-N'-(3,4-dimethoxybenzyl)urea;  
N-[3-(tert-butyl)-1H-pyrazol-5-yl]-N'-(4-chlorobenzyl)urea;  
N-[3-(tert-butyl)-1H-pyrazol-5-yl]-N'-(3,4-dihydroxybenzyl)urea;  
N-[3-(tert-butyl)-1H-pyrazol-5-yl]-N'-(3,4-dimethylbenzyl)urea;  
N-[3-(tert-butyl)-1H-pyrazol-5-yl]-N'-(3-chlorophenethyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-piperidinylmethyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-fluorobenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3,4-dimethoxybenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3,4-dimethylbenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-hydroxy-1-methyl-2-phenylethyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-[(1-ethyl-2-pyrrolidinyl)methyl]urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-[2-(2H-imidazol-4-yl)ethyl]urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-[2-(5-methoxy-1H-indol-3-yl)ethyl]urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1H-indol-6-yl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1,3-benzodioxol-5-ylmethyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-(4-morpholinyl)ethyl]urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-chlorobenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2,4-dichlorobenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-ethoxybenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3,4-dichlorobenzyl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-methoxybenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-fluorobenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-trifluoromethylbenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-methylbenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-4-morpholinecarboxamide;  
N-cyclobutyl-N'-(3-cyclopentyl-1H-pyrazol-5-yl)urea;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-1-pyrrolidinecarboxamide;  
4-(1,3-benzodioxol-5-ylmethyl)-N-(3-cyclopentyl-1H-pyrazol-5-yl)-1-piperazinecarboxamide;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-1-piperazinecarboxamide;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-4-phenyl-1-piperazinecarboxamide;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-4-methyl-1-piperazinecarboxamide;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-4-benzyl-1-piperazinecarboxamide;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-4-morpholinecarboxamide;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-1-piperidinecarboxamide;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-4-(aminomethyl)-1-piperidinecarboxamide;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-N'-(1-benzyl-4-piperidinyl)urea;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-N'-benzylurea;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-N'-phenethylurea;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-N'-(3,4-dimethoxyphenethyl)urea;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-N'-(4-hydroxyphenethyl)urea;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-N'-propylurea;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-N'-(4-hydroxybutylurea;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-4-[2-nitro-4-(trifluoromethyl)phenyl]-1-piperazinecarboxamide;  
N-(3-phenethyl-1H-pyrazol-5-yl)-1-pyrrolidinecarboxamide;  
4-(1,3-benzodioxol-5-yl-methyl)-N-(3-phenethyl-1H-pyrazol5-yl)-1-piperazinecarboxamide;  
N-(3-phenethyl-1H-pyrazol-5-yl)-1-piperazinecarboxamide;  
N-(3-phenethyl-1H-pyrazol-5-yl)-4-phenyl-1-piperazinecarboxamide;  
N-(3-phenethyl-1H-pyrazol-5-yl)-4-methyl-1-piperazinecarboxamide;  
N-(3-phenethyl-1H-pyrazol-5-yl)-4-benzyl-1-piperazinecarboxamide;  
N-(3-phenethyl-1H-pyrazol-5-yl)-4-morpholinecarboxamide;


N-(3-phenethyl-1H-pyrazol-5-yl)-1-piperidinecarboxamide;  
N-(3-phenethyl-1H-pyrazol-5-yl)-4-(aminomethyl)-1-piperidinecarboxamide;  
N-(3-phenethyl-1H-pyrazol-5-yl)-N'-benzylurea;  
N-(3-phenethyl-1H-pyrazol-5-yl)-N'-phenethylurea;  
N-(3-phenethyl-1H-pyrazol-5-yl)-N'-(3,4-dimethoxyphenethyl)urea;  
N-(3-phenethyl-1H-pyrazol-5-yl)-N'-(4-hydroxyphenethyl)urea;  
N-(3-phenethyl-1H-pyrazol-5-yl)-N'-propylurea;  
N-(3-phenethyl-1H-pyrazol-5-yl)-N'-(4-hydroxybutylurea;  
N-(3-phenethyl-1H-pyrazol-5-yl)-4-[2-nitro-4-(trifluoromethyl)phenyl]-1-piperazinecarboxamide;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-butylurea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2,4-dimethylphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3,4-dimethoxyphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-carboxyphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2,3-dimethylphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-carboxy-4-chlorophenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3,5-dimethylphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-carboxamidophenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-carboxy-4-hydroxyphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2,6-dimethylphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-cyanophenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-acetylphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1H-benzimidazol-6-yl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-hydroxy-3-methoxybenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-benzylurea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-{3-[3-(dimethylamino)-1-propynyl]phenyl}urea;  
N-[3-({[(3-cyclopropyl-1H-pyrazol-5-yl)amino]carbonyl}amino)phenyl]methanesulfonamide;  
2-[3-({[(3-cyclopropyl-1H-pyrazol-5-yl)amino]carbonyl}amino)anilino]acetamide;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-hydroxyphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-[3-(3-hydroxy-1-butynyl)phenyl]urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1H-indol-6-yl)urea;

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1H-indol-5-yl)urea;  
4-({[(3-cyclopropyl-1H-pyrazol-5-yl)amino]carbonyl}amino)benzenesulfonamide;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-methoxyphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-phenylurea;  
N-[4-({[(3-cyclopropyl-1H-pyrazol-5-yl)amino]carbonyl}amino)phenyl]-N-methylacetamide;  
N-(2-{[cyclohexyl(methyl)amino]methyl}phenyl)-N'-(3-cyclopropyl-1H-pyrazol-5-yl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-methoxyphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-chlorophenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-ethynylphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-aminophenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-hydroxy-4-methylphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-3-oxo-3,4-dihydro-1(2H)-quinoxalinecarboxamide;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-3,4-dihydro-2(1H)-isoquinolinecarboxamide;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-pyridinylmethyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-furylmethyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1,3-benzothiazol-5-yl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1,3-dimethyl-1H-pyrazol-5-yl)urea;  
N-[5-({[(3-cyclopropyl-1H-pyrazol-5-yl)amino]carbonyl}amino)-2-methoxyphenyl]acetamide;  
N-[3-({[(3-cyclopropyl-1H-pyrazol-5-yl)amino]carbonyl}amino)-4-methoxyphenyl]acetamide;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-aminophenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1H-imidazol-6-yl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-hydroxyphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-hydroxyphenyl)urea, and  
pharmaceutically acceptable salts thereof.

14. (Original) The method of Claim 1, wherein the mammal is a human.

15. (Currently Amended) A 3-ureido-pyrazole derivative represented by formula

(I):



wherein

R is a C<sub>3</sub>-C<sub>6</sub> cycloalkyl group, which is optionally substituted with a straight or branched C<sub>1</sub>-C<sub>6</sub> alkyl group, or is a C<sub>1</sub>-C<sub>6</sub> alkyl, aryl or arylalkyl group, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulphonyl, arylamino, arylcarbonyl, N-alkyl-piperazinyl, 4-morpholinyl, perfluorinated C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl, C<sub>2</sub>-C<sub>4</sub> aminoalkynyl or C<sub>2</sub>-C<sub>4</sub> hydroxyalkynyl substituents;

R<sub>1</sub> is -(CH<sub>2</sub>)<sub>n</sub>-R<sub>3</sub>;

n is 0 or an integer from 1 to 4;

R<sub>3</sub> is hydrogen, hydroxy, amino, or it is selected from the group consisting of cycloalkyl, aryl and heterocyclyl, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulphonyl, arylamino, arylcarbonyl, N-alkyl-piperazinyl, 4-morpholinyl, perfluorinated C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl, C<sub>2</sub>-C<sub>4</sub> aminoalkynyl or C<sub>2</sub>-C<sub>4</sub> hydroxyalkynyl substituents;

R<sub>2</sub> is hydrogen, or

R<sub>2</sub> and R<sub>1</sub>, together with the nitrogen atom to which they are bonded, form a heterocyclyl or heteroaryl group, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino,

alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulphonyl, arylamino, arylcarbonyl, N-alkyl-piperazinyl, 4-morpholinyl, perfluorinated C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, C<sub>2</sub>-C<sub>4</sub> alkynyl, C<sub>2</sub>-C<sub>4</sub> aminoalkynyl or C<sub>2</sub>-C<sub>4</sub> hydroxyalkynyl substituents;

or a pharmaceutically acceptable salt thereof;

provided that when n is 0 and R<sub>2</sub> is hydrogen, R is a C<sub>3</sub>-C<sub>6</sub> cycloalkyl group optionally substituted with a straight or branched C<sub>1</sub>-C<sub>6</sub> alkyl group.

16. (Original) The 3-ureido-pyrazole derivative of Claim 15, wherein

R is a C<sub>3</sub>-C<sub>6</sub> cycloalkyl or an optionally substituted straight or branched C<sub>1</sub>-C<sub>4</sub> alkyl group, a cycloalkyl group, an aryl group or an arylalkyl group;

R<sub>1</sub> is a C<sub>1</sub>-C<sub>4</sub> alkyl group or a phenyl, phenylalkyl, heteroaryl, heteroarylalkyl or heterocyclyl group, which is optionally substituted as defined in Claim 15;

or a pharmaceutically acceptable salt thereof.

17. (Original) The 3-ureido-pyrazole derivative of Claim 15, wherein

R is a C<sub>3</sub>-C<sub>6</sub> cycloalkyl;

R<sub>1</sub> is a C<sub>1</sub>-C<sub>4</sub> alkyl group substituted by hydroxy or amino, or is an aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the aryl or heterocyclyl moiety is selected from the group consisting of phenyl or optionally benzocondensed pyridine, indole, thiophene, thiazole, isoxazole, furane, piperidine, morpholine, each optionally further substituted;

or a pharmaceutically acceptable salt thereof.

18. (Currently Amended) The 3-ureido-pyrazole derivative of Claim 15, wherein R<sub>1</sub> and R<sub>2</sub>, together with the nitrogen atom to which they are bonded, form an optionally substituted heterocyclyl ring.

19. (Original) The 3-ureido-pyrazole derivative of Claim 15, wherein the heterocyclyl ring is such as piperidino, piperazino or morpholino.

20. (Original) The 3-ureido-pyrazole derivative of Claim 15, which is selected from the group consisting of

N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-[2-(1-piperidinyl)ethyl]urea;  
4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]carbonyl amino)methyl]benzenesulfonamide;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-[2-(2-pyridinyl)ethyl]urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-[2-(1-pyrrolidinyl)ethyl]urea;  
N-(3-chlorophenethyl)-N'-(3-cyclopropyl-1H-pyrazol-5-yl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2,3-dimethoxybenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-chlorobenzyl)urea;  
N-[3-(tert-butyl)-1H-pyrazol-5-yl]-N'-(4-piperidinylmethyl)urea;  
N-[3-(tert-butyl)-1H-pyrazol-5-yl]-N'-(3-fluorobenzyl)urea;  
N-[3-(tert-butyl)-1H-pyrazol-5-yl]-N'-(3,4-dimethoxybenzyl)urea;  
N-[3-(tert-butyl)-1H-pyrazol-5-yl]-N'-(4-chlorobenzyl)urea;  
N-[3-(tert-butyl)-1H-pyrazol-5-yl]-N'-(3,4-dihydroxybenzyl)urea;  
N-[3-(tert-butyl)-1H-pyrazol-5-yl]-N'-(3,4-dimethylbenzyl)urea;  
N-[3-(tert-butyl)-1H-pyrazol-5-yl]-N'-(3-chlorophenethyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-piperidinylmethyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-fluorobenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3,4-dimethoxybenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3,4-dimethylbenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-hydroxy-1-methyl-2-phenylethyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-[(1-ethyl-2-pyrrolidinyl)methyl]urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-[2-(2H-imidazol-4-yl)ethyl]urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-[2-(5-methoxy-1H-indol-3-yl)ethyl]urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1H-indol-6-yl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1,3-benzodioxol-5-ylmethyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-(4-morpholinyl)ethyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-chlorobenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2,4-dichlorobenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-ethoxybenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3,4-dichlorobenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-methoxybenzyl)urea;


N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-fluorobenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-trifluoromethylbenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-methylbenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-4-morpholinecarboxamide;  
N-cyclobutyl-N'-(3-cyclopentyl-1H-pyrazol-5-yl)urea;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-1-pyrrolidinecarboxamide;  
4-(1,3-benzodioxol-5-ylmethyl)-N-(3-cyclopentyl-1H-pyrazol-5-yl)-1-piperazinecarboxamide;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-1-piperazinecarboxamide;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-4-phenyl-1-piperazinecarboxamide;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-4-methyl-1-piperazinecarboxamide;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-4-benzyl-1-piperazinecarboxamide;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-4-morpholinecarboxamide;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-1-piperidinecarboxamide;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-4-(aminomethyl)-1-piperidinecarboxamide;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-N'-(1-benzyl-4-piperidinyl)urea;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-N'-benzylurea;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-N'-phenethylurea;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-N'-(3,4-dimethoxyphenethyl)urea;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-N'-(4-hydroxyphenethyl)urea;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-N'-propylurea;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-N'-(4-hydroxybutylurea;  
N-(3-cyclopentyl-1H-pyrazol-5-yl)-4-[2-nitro-4-(trifluoromethyl)phenyl]-1-piperazinecarboxamide;  
N-(3-phenethyl-1H-pyrazol-5-yl)-1-pyrrolidinecarboxamide;  
4-(1,3-benzodioxol-5-yl-methyl)-N-(3-phenethyl-1H-pyrazol-5-yl)-1-piperazinecarboxamide;  
N-(3-phenethyl-1H-pyrazol-5-yl)-1-piperazinecarboxamide;  
N-(3-phenethyl-1H-pyrazol-5-yl)-4-phenyl-1-piperazinecarboxamide;  
N-(3-phenethyl-1H-pyrazol-5-yl)-4-methyl-1-piperazinecarboxamide;  
N-(3-phenethyl-1H-pyrazol-5-yl)-4-benzyl-1-piperazinecarboxamide;  
N-(3-phenethyl-1H-pyrazol-5-yl)-4-morpholinecarboxamide;  
N-(3-phenethyl-1H-pyrazol-5-yl)-1-piperidinecarboxamide;

N-(3-phenethyl-1H-pyrazol-5-yl)-4-(aminomethyl)-1-piperidinecarboxamide;  
N-(3-phenethyl-1H-pyrazol-5-yl)-N'-benzylurea;  
N-(3-phenethyl-1H-pyrazol-5-yl)-N'-phenethylurea;  
N-(3-phenethyl-1H-pyrazol-5-yl)-N'-(3,4-dimethoxyphenethyl)urea;  
N-(3-phenethyl-1H-pyrazol-5-yl)-N'-(4-hydroxyphenethyl)urea;  
N-(3-phenethyl-1H-pyrazol-5-yl)-N'-propylurea;  
N-(3-phenethyl-1H-pyrazol-5-yl)-N'-(4-hydroxybutylurea;  
N-(3-phenethyl-1H-pyrazol-5-yl)-4-[2-nitro-4-(trifluoromethyl)phenyl]-1-piperazinecarboxamide;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-butylurea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2,4-dimethylphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3,4-dimethoxyphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-carboxyphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2,3-dimethylphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-carboxy-4-chlorophenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3,5-dimethylphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-carboxamidophenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-carboxy-4-hydroxyphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2,6-dimethylphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-cyanophenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-acetylphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1H-benzimidazol-6yl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-hydroxy-3-methoxybenzyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-benzylurea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-[3-(dimethylamino)-1-propynyl]phenyl)urea;  
N-[3-({[(3-cyclopropyl-1H-pyrazol-5-yl)amino]carbonyl}amino)phenyl]methanesulfonamide;  
2-[3-({[(3-cyclopropyl-1H-pyrazol-5-yl)amino]carbonyl}amino)anilino]acetamide;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-hydroxyphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-(3-hydroxy-1-butynyl)phenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1H-indol-6-yl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1H-indol-5-yl)urea;

4-({[(3-cyclopropyl-1H-pyrazol-5-yl)amino]carbonyl}amino)benzenesulfonamide;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-methoxyphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-phenylurea;  
N-[4-({[(3-cyclopropyl-1H-pyrazol-5-yl)amino]carbonyl}amino)phenyl]-N-methylacetamide;  
N-(2-{{cyclohexyl(methyl)amino}methyl}phenyl)-N'-(3-cyclopropyl-1H-pyrazol-5-yl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-methoxyphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-chlorophenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-ethynylphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-aminophenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-hydroxy-4-methylphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-3-oxo-3,4-dihydro-1(2H)-quinoxalinecarboxamide;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-3,4-dihydro-2(1H)-isoquinolinecarboxamide;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-pyridinylmethyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(2-furylmethyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1,3-benzothiazol-5-yl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1,3-dimethyl-1H-pyrazol-5-yl)urea;  
N-[5-({[(3-cyclopropyl-1H-pyrazol-5-yl)amino]carbonyl}amino)-2-methoxyphenyl]acetamide;  
N-[3-({[(3-cyclopropyl-1H-pyrazol-5-yl)amino]carbonyl}amino)-4-methoxyphenyl]acetamide;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-aminophenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(1H-imidazol-6-yl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(3-hydroxyphenyl)urea;  
N-(3-cyclopropyl-1H-pyrazol-5-yl)-N'-(4-hydroxyphenyl)urea, and  
pharmaceutically acceptable salts thereof.

21. (Original) A process for preparing the 3-ureido-pyrazole derivative of Claim 15, or a pharmaceutically acceptable salt thereof, comprising:


(a) reacting a compound represented by formula (II):



with a compound represented by formula (III):



wherein R and R<sub>1</sub> are as defined in Claim 15,




to produce a compound represented by formula (IV):

wherein R and R<sub>1</sub> are as defined in Claim 15; and

(b) selectively hydrolyzing a compound represented by formula (IV) in a basic medium to produce a compound represented by formula (I).


22. (Original) A process for preparing the 3-ureido-pyrazole derivative of Claim 15, or a pharmaceutically acceptable salt thereof, comprising:



(c) reacting a compound represented by formula (V):

wherein R is defined in Claim 15,

with 4-nitrophenyl chloroformate, or a polymer supported form of 4-nitrophenyl chloroformate, to produce a compound represented by formula (VI), or a polymer supported form of the compound represented by formula (VI):




wherein R is defined in Claim 15;

(d) reacting a compound represented by formula (VI) with a compound represented by formula (VII):



wherein R<sub>1</sub> and R<sub>2</sub> are as defined in Claim 15,



to produce a compound represented by formula (VIII):

wherein R, R<sub>1</sub> and R<sub>2</sub> are as defined in Claim 15;

(e) hydrolizing a compound represented by formula (VIII) in acidic medium to produce a compound represented by formula (I); and, optionally, converting the 3-ureido-pyrazole derivative represented by formula (I) into another derivative represented by formula (I), and/or into a salt thereof.

23. (Original) A pharmaceutical composition, comprising the 3-ureido-pyrazole derivative of Claim 15 and at least one pharmaceutically acceptable carrier and/or diluent.